TABLE 2.
Participant demographic and treatment information
| Variable | n (%) | Mean (SD) | Range |
|---|---|---|---|
| Current age | 18 (100.0) | 17.94 (2.31) | 15.00–22.00 |
| Age at diagnosis | 18 (100.0) | 15.89 (2.54) | 9.00–20.00 |
| Sex (female) | 4 (22.2) | - | - |
| Ethnicity (Hispanic) | 5 (27.8) | - | - |
| Race | |||
| White/Caucasian | 12 (66.7) | - | - |
| Black/African American | 2 (11.1) | - | - |
| Asian | 1 (5.6) | - | - |
| Other | 3 (16.7) | - | - |
| Primary insurance type (public) | 7 (38.9) | - | - |
| Took 6MP in the evening (8–11 PM) | 16 (88.9) | - | - |
| Treated on a clinical trial | 3 (16.7) | - | - |
| Months since diagnosis | 18 (100.0) | 20.41 (8.52) | 11.03–37.80 |
| Cycle of maintenance | 18 (100.0) | 4.67 (3.27) | 1.00–11.00 |
| Number of missed 6MP doses (MEMS) | 15 (83.3) | 2.60 (3.09) | 0.00–10.00 |
| Number of missed 6MP doses (EMA) | 18 (100) | 0.89 (1.64) | 0.00–7.00 |
| Number of missed 6MP doses (provider) | 16 (88.9) | 0.63 (0.96) | 0.00–3.00 |